GASTROINTESTINAL PHARMACOLOGY Charles Nichols Ph D Department of

  • Slides: 59
Download presentation
GASTROINTESTINAL PHARMACOLOGY Charles Nichols, Ph. D Department of Pharmacology & Experimental Therapeutics LSUHSC, New

GASTROINTESTINAL PHARMACOLOGY Charles Nichols, Ph. D Department of Pharmacology & Experimental Therapeutics LSUHSC, New Orleans, LA 70112

The Gastrointestinal Tract

The Gastrointestinal Tract

GASTROINTESTINAL DISORDERS • Gastroesophageal Reflux Disease (GERD) • Peptic Ulcer Disease (PUD) • Duodenal

GASTROINTESTINAL DISORDERS • Gastroesophageal Reflux Disease (GERD) • Peptic Ulcer Disease (PUD) • Duodenal Ulcer • Nausea • Emesis • IBS • Diarrhea • Constipation

Stomach

Stomach

Stomach Lining Basics

Stomach Lining Basics

Gastric Gland

Gastric Gland

Gastric Mucosal Barrier • Surface mucosa cells in the pyloric region secrete a thick,

Gastric Mucosal Barrier • Surface mucosa cells in the pyloric region secrete a thick, alkaline-rich mucus that protects the epithelium of the stomach and duodenum from harsh acid conditions of the lumen. • This is known as the gastric mucosal barrier. • These cells are stimulated by mechanical and chemical irritation and parasympathetic inputs. • This protective mucus barrier can be damaged by bacterial and viral infection, certain drugs, and aspirin.

Parietal Cell: Gastric Acid Secretion H+

Parietal Cell: Gastric Acid Secretion H+

Chief Cell: Synthesis and Activation of Pepsin HCl +HCl Pepsin

Chief Cell: Synthesis and Activation of Pepsin HCl +HCl Pepsin

Serotonin (5 -Hydroxytryptamine) • Key neurotransmitter in the intestine • Present in abundance within

Serotonin (5 -Hydroxytryptamine) • Key neurotransmitter in the intestine • Present in abundance within the gut • Most is stored in enterochromaffin cell granules • Released by many stimuli - most potently by mucosal stroking • Serotonin stimulates enteric nerves to initiate secretion and propulsive motility

Serotonin in the Gut

Serotonin in the Gut

Serotonin Dysfunction in the Gut

Serotonin Dysfunction in the Gut

Gastroesophageal Reflux Disease (GERD) -Backflow of stomach acid into the esophagus -Esophagus is not

Gastroesophageal Reflux Disease (GERD) -Backflow of stomach acid into the esophagus -Esophagus is not equipped to handle stomach acid => scaring -Usual symptom is heartburn, an uncomfortable burning sensation behind the breastbone (MI often mistaken for GERD !) -More severe symptoms: difficulty swallowing, chest pain -Reflux into the throat can cause sore throat -Complications include esophageal erosions, esophageal ulcer and narrowing of the esophagus (esophageal stricture) -In some patients (~10%), the normal esophageal lining or epithelium may be replaced with abnormal (Barrett's) epithelium. This condition (Barrett's esophagus) has been linked to cancer of the esophagus.

Gastroesophageal Reflux Disease (GERD) Endoscope of Barrett’s Esophagus (can become malignant - needs monitoring)

Gastroesophageal Reflux Disease (GERD) Endoscope of Barrett’s Esophagus (can become malignant - needs monitoring)

Gastroesophageal Reflux Disease (GERD) Precipitants: § Food (fatty food, alcohol, caffeine) § Smoking §

Gastroesophageal Reflux Disease (GERD) Precipitants: § Food (fatty food, alcohol, caffeine) § Smoking § Obesity § Pregnancy Usually chronic relapsing course

Peptic Ulcer Disease Benign PUD: Normal gastric acid production however the mucosal barrier is

Peptic Ulcer Disease Benign PUD: Normal gastric acid production however the mucosal barrier is weak. Malignant PUD: Excessive secretion of gastric Acid that overwhelms the mucosal barrier.

Treatment of Heartburn, GERD and PUD Antacids H 2 Receptor Blockers Mucosal Protective Agents

Treatment of Heartburn, GERD and PUD Antacids H 2 Receptor Blockers Mucosal Protective Agents Proton Pump Inhibitors Anti-cholinergics Prostaglandin Analogs Anti-microbial Agents

Antacids Systemic Antacid: Sodium Bicarbonate Nonsystemic Antacid: Aluminum Hydroxide + Magnesium Hydroxide Combinations (Maalox

Antacids Systemic Antacid: Sodium Bicarbonate Nonsystemic Antacid: Aluminum Hydroxide + Magnesium Hydroxide Combinations (Maalox and Mylanta) Contraindicated in patients with impaired renal function Magnesium may cause diarrhea Calcium Carbonate (Tums) Calcium may cause constipation

ANTACID NEUTRALIZING CAPACITY (ANC) Amount of 1 N HCl(meq) brought to p. H 3.

ANTACID NEUTRALIZING CAPACITY (ANC) Amount of 1 N HCl(meq) brought to p. H 3. 5 by an antacid solution within 15 min. FDA requires a Min=5 meq/dose As the ANC number increases the neutralizing capacity of an antacid increases. Maalox TC=28 Mylanta DS=23 Tums EX=15

Histamine H 2 Receptor Blockers • Inhibit secretion of gastric acid through competitive inhibition

Histamine H 2 Receptor Blockers • Inhibit secretion of gastric acid through competitive inhibition of Histamine H 2 receptors • Prevention & tx of PUD, Esophagitis, GI bleeding, stress ulcers, and Zollinger. Ellison Syndrome • May alter the effects of other drugs through interactions with CYP 450 (especially cimetidine) • Very few side effects (except for cimetidine - inhibits metabolism of estrogen) • Suppresses 24 hour gastric secretion by 70% Cimetidine Famotidine Ranitidine Nizatidine

Proton Pump Inhibitors • Strong inhibitors of gastric acid secretion through irreversible inhibition of

Proton Pump Inhibitors • Strong inhibitors of gastric acid secretion through irreversible inhibition of proton pump, preventing “pumping” or release of gastric acid (24 hr action) • Indicated in PUD, Gastritis, GERD, & Zollinger-Ellison syndrome • Faster relief and healing than H 2 receptor blockers • Decreases acid secretion by up to 95% for up to 48 hours • 4 -8 week course of treatment Omeprazole Lansoprazole Rebeprazole Esomeprazole Pantoprazole

Prostaglandins • Misoprostol • PGE 1 analog • Stimulates Gi pathway, leading to decrease

Prostaglandins • Misoprostol • PGE 1 analog • Stimulates Gi pathway, leading to decrease in gastric acid release • For treatment of NSAID induced injury • Side effects include diarrhea, pain, and cramps (30%) • Do not give to women of childbearing years unless a reliable method of birth control can be DOCUMENTED • Can cause birth defects, and premature birth Misoprostol

Anticholinergics • Pirenzipine • Muscarinic M 1 acetylcholine receptor antagonist • Blocks gastric acid

Anticholinergics • Pirenzipine • Muscarinic M 1 acetylcholine receptor antagonist • Blocks gastric acid secretions • About as effective as H 2 blockers • Rarely used, primarily as adjunct therapy • Anticholinergic side effects (anorexia, blurry vision, constipation, dry mouth, sedation)

Summary of Acid Reduction therapeutics Antacids H+ Cl-

Summary of Acid Reduction therapeutics Antacids H+ Cl-

 • • Sucralfate (carafate) • Can be used to prevent & treat PUD

• • Sucralfate (carafate) • Can be used to prevent & treat PUD • It requires an acid Ph to activate • Forms sticky polymer in acidic environment and adheres to the ulcer site, forming a barrier • May bind with other drugs and interfere with absorption • Give approximately 2 hours before or after other drugs • Take on an empty stomach before meals Chelated Bismuth • Protects the ulcer crater and allows healing • Some activity against H. pylori • Should not be used repeatedly or for more than 2 months at a time • Can cause black stools, constipation

Helicobacter pylori H. pylori are bacteria able to attach to the epithelial cells of

Helicobacter pylori H. pylori are bacteria able to attach to the epithelial cells of the stomach and duodenum which stops them from being washed out of the stomach. Once attached, the bacteria start to cause damage to the cells by secreting degradative enzymes, toxins and initiating a self-destructive immune response. www. science. org. au/ nobel/2005/images/invasion. jpg

Anti-H. pylori Therapy • >85% PUD caused by H. pylori • Antibiotic Ulcer Therapy

Anti-H. pylori Therapy • >85% PUD caused by H. pylori • Antibiotic Ulcer Therapy - Used in Combinations • Bismuth - Disrupts bacterial cell wall • Clarithromycin - Inhibits protein systhesis • Amoxicillin - Disrupts cell wall • Tetracycline - Inhibits protein synthesis • Metronidazone - Used often due to bacterial resistance to amoxicillin and tetracycline, or due to intolerance Triple Therapy - 7 day treatment - Effective 80 -85% Proton pump inhibitor + amoxicillin/tetracycline + metronidazone/clarithomycin Quadruple Therapy - 3 day treatment, as efficacious as triple therapy - Add Bismuth to triple therapy

Moving down the system. . .

Moving down the system. . .

Inflammatory Bowel Disease • • Ulcerative colitis • Diffuse mucosal inflammation limited to the

Inflammatory Bowel Disease • • Ulcerative colitis • Diffuse mucosal inflammation limited to the colon • Bloody diarrhea, colicky pain, urgency, tenesmus Crohn’s Disease • Patchy transmural inflammation • May affect any part of GI tract • Abdominal pain, diarrhea, weight loss, intestinal obstruction

Inflammatory Bowel Disease Treatment = Resolve acute episodes and prolong remission Therapeutics: • Aminosalicylates

Inflammatory Bowel Disease Treatment = Resolve acute episodes and prolong remission Therapeutics: • Aminosalicylates - for mild symptoms • Corticosteroids - for moderate symptoms • Thiopurines - for active and chronic symptoms • Methotrexate - for active and chronic symptoms • Cyclosporin - for active and chronic symptoms refractory to corticorsteroids - (significant side effects) • Infliximab - antibody infusion

Aminosalicylates • Sulfasalazine (5 -aminosalicylic acid and sulfapyridine as carrier substance) Mesalazine (5 -ASA),

Aminosalicylates • Sulfasalazine (5 -aminosalicylic acid and sulfapyridine as carrier substance) Mesalazine (5 -ASA), eg Asacol, Pentasa Balsalazide (prodrug of 5 -ASA) Olsalazine (5 -ASA dimer cleaves in colon) • Oral, rectal preparation • Use • • Maintaining remission Active disease May reduce risk of colorectal cancer Adverse effects • • • 10 -45% Nausea, headache, epigastric pain, diarrhoea, hypersensitivity, pancreatitis, blood disorders, lung disorders, myo/pericarditis Caution in renal impairment, pregnancy, breast feeding

Corticosteroids • Anti-inflammatory agents for moderate to severe relapses • eg 40 mg Prednisolone

Corticosteroids • Anti-inflammatory agents for moderate to severe relapses • eg 40 mg Prednisolone • Inhibition of inflammatory pathways (↓IL transcription, suppression of arachidonic acid metabolism, lymphocyte apoptosis) • Side effects • Acne, moon face • Sleep, mode disturbance • Dyspepsia, glucose intolerance • Cataracts, osteoporosis, myopathy…

Thiopurines Azathioprine, mercaptopurine • Inhibit ribonucleotide synthesis • Inducing T cell apoptosis by modulating

Thiopurines Azathioprine, mercaptopurine • Inhibit ribonucleotide synthesis • Inducing T cell apoptosis by modulating cell signalling • Azathioprine metabolised to mercaptopurine and 6 -thioguanine nucleotides Use • • Active and chronic disease Steroid sparing Side effects • • • Leucopaenia (myelotoxic) Monitor for signs of infection, sore throat Flu like symptoms after 2 to 3 weeks, liver, pancreas toxicity

Methotrexate • • Inhibits dihydrofolate reductase Probably inhibition of cytokine and eicosanoid synthesis Use

Methotrexate • • Inhibits dihydrofolate reductase Probably inhibition of cytokine and eicosanoid synthesis Use • • • Relapsing or active CD refractory or intolerant to AZA or thiopurine Side effects • • GI Hepatotoxicity, pneumonitis

Cyclosporin • Inhibitor of calcineurin, preventing clonal expansion of T cell subsets • Use

Cyclosporin • Inhibitor of calcineurin, preventing clonal expansion of T cell subsets • Use • • • Active and chronic disease • Steroid sparing • Bridging therapy Side effects • Tremor, paraesthesiae, malaise, headache, abnormal LFT • Gingival hyperplasia, hirsutism • Major: renal impairment, infections, neurotoxicity Monitor • Blood pressure, FBC, renal function

Infliximab • Anti TNF-α monoclonal antibody • Potent anti inflammatory effects • Use •

Infliximab • Anti TNF-α monoclonal antibody • Potent anti inflammatory effects • Use • Fistulizing CD • Severe active CD refractory/intolerant of steroids or immunosuppression • iv infusion • Side effects • Infusion reactions • Sepsis • Reactivation of Tb, increased risk of Tb

Constipation

Constipation

Constipation • Usually effectively treated with dietary modification. • Only if this fails should

Constipation • Usually effectively treated with dietary modification. • Only if this fails should laxatives be used. • The #1 cause of constipation in laxative abuse! Therapy: 1. Bulking agents 2. Osmotic laxatives 3. Stimulant drugs 4. Stool softners

Laxatives

Laxatives

Bulk Laxatives -Increase in bowel content volume triggers stretch receptors in the intestinal wall

Bulk Laxatives -Increase in bowel content volume triggers stretch receptors in the intestinal wall -Causes reflex contraction (peristalsis) that propels the bowel content forward Psyllium Bran Methylcellulose • Insoluble and non-absorbable • Non digestible • Must be taken with lots of water! (or it will make constipation worse)

Saline and Osmotic Laxatives -Effective in 1 -3 hours -Used to purge intestine (e.

Saline and Osmotic Laxatives -Effective in 1 -3 hours -Used to purge intestine (e. g. surgery, poisoning) -Fluid is drawn into the bowel by osmotic force, increasing volume and triggering peristalsis • Nondigestible sugars and alcohols • Lactulose (broken down by bacteria to acetic and lactic acid, which causes the osmotic effect) • Salts • Milk of Magnesia (Mg(OH)2) • Epsom Salt (Mg. SO 4) • Glauber’s Salt (Na 2 SO 4) • Sodium Phosphates (used as enema) • Sodium Citrate (used as enema) • Polyethylene glycol

Stool Softners - Emollients • Docusate sodium (surfactant and stimulant) • Liquid Paraffin (oral

Stool Softners - Emollients • Docusate sodium (surfactant and stimulant) • Liquid Paraffin (oral solution) • Glycerin suppositories Docusate

Irratant/Stimulant Laxatives-Cathartics -Increases intestinal motility -Irritate the GI mucosa and pull water into the

Irratant/Stimulant Laxatives-Cathartics -Increases intestinal motility -Irritate the GI mucosa and pull water into the lumen -Indicated for severe constipation where more rapid effect is required (6 -8 hours) • Castor Oil - From the Castor Bean • Senna - Plant derivative • Bisacodyl • Lubiprostone -PGE 1 derivative that stimulates chloride channels, producing chloride rich secretions Bisacodyl Senna Lubiprostone

Laxative Abuse • Most common cause of constipation! • Longer interval needed to refill

Laxative Abuse • Most common cause of constipation! • Longer interval needed to refill colon is misinterpreted as constipation => repeated use • Enteral loss of water and salts causes release of aldosterone => stimulates reabsorption in intestine, but increases renal excretion of K+ => double loss of K+ causes hypokalemia, which in turn reduces peristalsis. =>This is then often misinterpreted as constipation => repeated laxative use

Diarrhea

Diarrhea

Diarrhea • Caused by: • Toxins • Microorganims (shigella, salmonella, E. coli, campylobacter, clostridium

Diarrhea • Caused by: • Toxins • Microorganims (shigella, salmonella, E. coli, campylobacter, clostridium difficile) • Antibiotic associated colitis • Indications for treatment • >2 -3 days • Severe diarrhea in the elderly or small children • Chronic inflammatory disease • When the specific cause has been determined

Anti-Diarrheal Agents • Anti-motility Agents • Reduce peristalsis by stimulating opioid receptors in the

Anti-Diarrheal Agents • Anti-motility Agents • Reduce peristalsis by stimulating opioid receptors in the bowel • Allow time for more water to be absorbed by the gut • Morphine • Codeine • Diphenoxylate • Loperamide n 40 -50 x more potent than morphine n Poor CNS penetration n Increases transit time and sphincter tone n Antisecretory against cholera toxin and some E. coli toxin n T½ 11 hours, dose: 4 mg followed by 2 mg doses (16 mg/d max) Overdose: paralytic ileus, CNS depression Caution in IBD (toxic megacolon) n n • Contraindications for antidiarrheals • Toxic Materials • Microorganisms (salmonella, E. coli) • Antibiotic associated Loperamide

Clostridium Difficile • The major cause of diarrhea and colitis in patients exposed to

Clostridium Difficile • The major cause of diarrhea and colitis in patients exposed to antibiotics (~20%). • Fecal - oral route of transmission • Three steps to infection • Alteration of normal fecal flora • Colonic colonization of C. difficile • Growth and production of toxins • Infection can lead to formation of colitis and toxic megacolon • Pharmacological Treatment • Discontinue offending antibiotic • Metronidazole (contraindicated in patients with liver or renal impairment) • Vancomycin (contraindicated in patients with renal impairment)

Antiflatulants (Le Pétomane)

Antiflatulants (Le Pétomane)

Antiflatulants • Used to relieve the painful symptoms associated with gas • Simethicone (a

Antiflatulants • Used to relieve the painful symptoms associated with gas • Simethicone (a detergent) • Alters elasticity of mucus-coated bubbles, causing them to break • Large bubbles -> smaller bubbles, and less pain • Used often, but limited data regarding effectiveness Simethicone

Emesis (Vomiting)

Emesis (Vomiting)

Emesis (seeing something repulsive) (motion sickness) (Ingesting a toxin)

Emesis (seeing something repulsive) (motion sickness) (Ingesting a toxin)

Syrup of Ipecac Emetic • Prepared from the root of the ipecacuanha plant •

Syrup of Ipecac Emetic • Prepared from the root of the ipecacuanha plant • Induces emesis • Side effects include drowsiness, diarrhea, and stomach ache • Acceptable for use when: • There is no contraindication to the use of ipecac • There is substantial risk of serious toxicity to the victim • There is no alternative therapy available or effective to decrease gastrointestinal absorption (e. g. , activated charcoal) • There will be a delay of greater than 1 hour before the patient will arrive at an emergency medical facility and ipecac syrup can be administered within 30 -90 minutes of the ingestion • Ipecac syrup administration will not adversely affect more definitive treatment that might be provided at a hospital

Antiemetic Therapuetics • Muscarinic M 1 receptor antagonist • Scopolamine • Side Effects: •

Antiemetic Therapuetics • Muscarinic M 1 receptor antagonist • Scopolamine • Side Effects: • Dry Mouth • Dizziness • Restlessness • Dilated Pupils • Delirium at high doses • Allergic Reaction • Contraindications • Kidney or liver disease • Enlarged prostate • Difficulty in urination / bladder problems • Heart Disease

Antiemetic Therapuetics • Histamine H 1/Dopamine D 2 receptor antagonist • Phenothiazines • Promethazine

Antiemetic Therapuetics • Histamine H 1/Dopamine D 2 receptor antagonist • Phenothiazines • Promethazine (Phenergan) • Prochlorperazine (Compazine) • Side Effects • These drugs are neuroleptics (typical antipsychotics) • Blurred vision • Dry mouth • Dizziness • Restlessness • Seizures • Extrapyramidal effects - Tardive dyskinesia (long term treatment) • Contraindications • Allergy to phenthiazines • Glaucoma • Liver disease

Antiemetic Therapuetics • Serotonin 5 -HT 3 receptor antagonist • Ondansetron (Zofran) • Granisetron

Antiemetic Therapuetics • Serotonin 5 -HT 3 receptor antagonist • Ondansetron (Zofran) • Granisetron • Excellent for chemotherapy induced nausea and vomiting • Side Effects • Very few common side effects - usually well tolerated • Headache • Constipation • Rarely • Hiccups • Itchiness • Transient blindness

Antiemetic Therapeutic Sites - Summary Cancer Chemotherapy Drugs Dopamine agonists Chemoreceptor Trigger Zone (CTZ)

Antiemetic Therapeutic Sites - Summary Cancer Chemotherapy Drugs Dopamine agonists Chemoreceptor Trigger Zone (CTZ) Scopolamine H 1 Antihistamines Ondansetron Phenothiazines All Ondansetron